维利西呱在射血分数降低心衰患者中的成本效益:VICTORIA随机临床试验
基于VICTORIA试验(N=5050)的卫生经济学分析,从美国医疗保健部门视角评估维利西呱对比安慰剂的成本效益。维利西呱具有中等价值,但成本效益估计对是否考虑NT-proBNP疗效异质性敏感。
要点
- 维利西呱在VICTORIA试验中满足中等价值标准。
- 成本效益估计对是否纳入NT-proBNP疗效异质性敏感。
- 成本效益主要由最低三个NT-proBNP四分位患者的预期寿命增量驱动。
核心结论
- 维利西呱在VICTORIA试验中满足中等价值标准,但增量成本效益比估计对是否考虑NT-proBNP疗效异质性敏感。
- 维利西呱的成本效益主要由最低三个NT-proBNP四分位患者的预期寿命增量驱动。
研究设计与样本
- 基于VICTORIA随机临床试验(N=5050)的卫生经济学分析,收集全部患者的医疗资源使用数据。
- 成本通过外部来源的美国成本权重应用于资源使用计数进行估计,寿命预期基于患者层面经验性试验生存结果采用年龄基础生存建模方法投影。
- 质量调整基于前瞻性收集的EQ-5D效用值,主要结局为增量成本效益比,从美国医疗保健部门视角评估终生时间范围。
主要发现
- 纳入治疗与基线NT-proBNP交互项时,维利西呱组估计质量调整寿命为4.56 QALYs,安慰剂组为4.13 QALYs,增量贴现QALY为0.43。
- 不纳入治疗异质性/交互项时,维利西呱组为4.50 QALYs,安慰剂组为4.33 QALYs,增量贴现QALY为0.17。
关键数值与推荐
- 预设分析显示,维利西呱在较低NT-proBNP四分位组显示生存获益(风险比0.82 [95% CI, 0.69-0.97]),在最高NT-proBNP四分位组无获益(风险比1.14 [95% CI, 0.95-1.38])。
- 全因死亡风险比为0.95(95% CI, 0.84-1.07)。
临床怎么用
- 维利西呱的成本效益评估需考虑基线NT-proBNP水平相关的疗效异质性。
- 对于NT-proBNP处于最低三个四分位的患者,维利西呱可能更具成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The VICTORIA trial (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) demonstrated that, in patients with high-risk heart failure, vericiguat reduced the primary composite outcome of cardiovascular death or heart failure hospitalization relative to placebo. The hazard ratio for all-cause mortality was 0.95 (95% CI, 0.84-1.07). In a prespecified analysis, treatment effects varied substantially as a function of baseline NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels, with survival benefit for vericiguat in the lower NT-proBNP quartiles (hazard ratio, 0.82 [95% CI, 0.69-0.97]) and no benefit in the highest NT-proBNP quartile (hazard ratio, 1.14 [95% CI, 0.95-1.38]). An economic analysis was a major secondary objective of the VICTORIA research program. METHODS: Medical resource use data were collected for all VICTORIA patients (N=5050). Costs were estimated by applying externally derived US cost weights to resource use counts. Life expectancy was projected from patient-level empirical trial survival results with the use of age-based survival modeling methods. Quality-of-life adjustments were based on prospectively collected EQ-5D-based utilities. The primary outcome was the incremental cost-effectiveness ratio, comparing vericiguat with placebo, assessed from the US health care sector perspective over a lifetime horizon. Cost-effectiveness was estimated using the total VICTORIA cohort, both with and without interaction between treatment and baseline NT-proBNP. RESULTS: Life expectancy modeling results varied according to whether the observed heterogeneity of treatment effect by baseline NT-proBNP values was incorporated into the modeling. Including the interaction term, the vericiguat arm had an estimated quality-adjusted life expectancy of 4.56 quality-adjusted life-years (QALYs) compared with 4.13 QALYs for placebo (incremental discounted QALY, 0.43). Without the treatment heterogeneity/interaction term, vericiguat had 4.50 QALYs compared with 4.33 QALYs for placebo (incremental discounted QALY, 0.17). Incremental discounted costs (vericiguat minus placebo) were $28 546 with the treatment interaction and $20 948 without it. Corresponding incremental cost-effectiveness ratios were $66 509 per QALY allowing for treatment heterogeneity and $124 512 without heterogeneity. CONCLUSIONS: Vericiguat use in the VICTORIA trial met criteria for intermediate value, but the incremental cost-effectiveness ratio estimates were sensitive to whether the analysis accounted for observed NT-proBNP treatment effect heterogeneity. The cost-effectiveness of vericiguat was driven by the projected incremental life expectancy among patients in the lowest 3 quartiles of NT-proBNP. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02861534.
引用
- Chew, Li, Bigelow, et al. Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial. Circulation. 2023. PMID: 37671551. doi:10.1161/CIRCULATIONAHA.122.063602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。